Clemens Zwergel from Sapienza University, Italy, and Marius Hittinger from PharmBioTec gGmbH, have unveiled together with researchers from a multinational team at the Jagiellonian University, Poland and Universität des Saarlandes, Germany innovative small molecules in the fight against Alzheimer’s disease (AD). Their collaborative work explores a new series of Selenium-containing 5-HT6R ligands targeting the serotonin receptor 5-HT6 for AD treatment.
This research, surpassing the effects of the approved drug donepezil in a rodent model, marks a significant stride toward addressing both the causes and symptoms of AD. It opens the door to potential advancements in AD therapy, showcasing the impactful collaboration between academia and industry.
Read the full article here: https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c02148
Kudos to all the researchers involved for their dedication to advancing Alzheimer’s research!
